Authors
Latest:
Dr Bardia on Findings From DESTINY-Breast06 in HER2-Low Breast CancerAditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.
Latest:
The Future of Advanced Renal Cell Carcinoma ManagementDrs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.
Latest:
Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain MetastasesBrian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.
Latest:
Mapping Progress in Pancreatic Cancer Surgery: Leveraging New TechnologyIn this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.
Latest:
Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLCMichael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.
Latest:
Dr. Sanjana on the Use of Whole-Exome Sequencing to Predict Immunotherapy Response in Advanced TumorsNeville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.
Latest:
Dr. Lee on Treatment Considerations in Smoldering Multiple MyelomaSarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.
Latest:
Dr Mead on Unanswered Questions in the Treatment of MCLMonica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.
Latest:
Closing Thoughts on Evolving Antibody-Drug Conjugate LandscapeThe expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Latest:
Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C MelanomaBrian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.
Latest:
Dr. Cohen on Potential With CAR T-Cell Therapy in Medullary Thyroid CancerRoger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
Latest:
Dr. Khoury on the Importance of Differentiating Between BPDCN and AMLJoseph D. Khoury, MD, discusses the importance of differentiating between blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.
Latest:
Small Clones, Outsized Consequences: The Many Faces of Clonal HematopoiesisDanielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.
Latest:
Dr Gondi on Prophylactic Cranial Irradiation With Hippocampal Avoidance in SCLCVinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.
Latest:
Dr. Masrouha on the Challenges of Surgical Removal of Chordoma TumorsKarim Masrouha, MD, discusses the challenges of surgically removing chordoma tumors.
Latest:
Dr Yang on the Results of the KEYNOTE-789 Trial in EGFR-mutant NSCLCJames Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.
Latest:
Dr Jain on the Impact of CD39+ T Cells on CAR T-Cell PhenotypeMichael Jain, MD, discusses the importance of evaluating the impact of lymphoma-associated CD39-positive T cells on CAR T-cell phenotypes.
Latest:
Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast CancerHemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.
Latest:
Dr. Bach on Examining ctDNA in CRCSander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.
Latest:
The Future of AYA ALLThe panel concludes its discussion with a look at the future of AYA ALL treatment and the role of clinical trials and innovative therapies in improving outcomes for patients.
Latest:
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital ChaplaincyCamidge and Cooper discuss Cooper’s career as a hospital chaplain, the focus of her writing, and the importance of meeting patients where they are.
Latest:
Dr. El Chaer on the Role of Next-Generation Sequencing in MPNsFiras El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.
Latest:
Best Practices in Managing Patients on CapivasertibPanelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.
Latest:
Dr Niikura on T-DXd in Patients With HER2+ Breast Cancer With Brain Metastases and Leptomeningeal DiseaseNaoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.
Latest:
Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRCKathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer
Latest:
Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade GliomaSarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.
Latest:
Stage Is Set for Continued Progress in the Melanoma ClinicUnprecedented treatment advances have been made during the last decade for patients with advanced melanoma.
Latest:
Dr. Palta on the Clinical Implications of the NRG/RTOG 1112 Trial in HCCManisha Palta, MD, discusses the clinical implications of the phase 3 NRG/RTOG 1112 trial in patients with locally advanced hepatocellular carcinoma.
Latest:
Dr. Piccirillo on the Safety Profile of Bevacizumab Plus Erlotinib in EGFR+ Nonsquamous NSCLCMaria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.
